Type 2 Diabetes

Overview

Type 2 diabetes is driven by progressive insulin resistance and beta-cell dysfunction. The GLP-1/GIP/glucagon receptor agonist class represents the most transformative development in diabetes pharmacology in decades, addressing both the glycemic and cardiometabolic dimensions of the disease. Mitochondrial peptides offer complementary mechanisms for improving cellular insulin sensitivity independent of receptor agonism.

Recommended Peptides

• Retatrutide – triple agonist; most powerful glucose-lowering peptide available; also addresses obesity which is often the root cause of T2D
• Semaglutide – FDA-approved for T2D; reduces HbA1c by 1.5-2%; also reduces major adverse cardiovascular events (MACE); Ozempic
• Tirzepatide – FDA-approved for T2D (Mounjaro); dual GLP-1/GIP agonist; superior HbA1c reduction vs semaglutide; also FDA-approved for obesity as Zepbound
• CagriSema – cagrilintide (amylin analogue) + semaglutide; additive glucose lowering through distinct satiety mechanisms
• MOTS-C – mitochondrial peptide acting as an exercise mimetic; improves peripheral glucose uptake and insulin sensitivity without receptor agonism; can complement GLP-1 agonists
• 5-Amino-1MQ – NNMT inhibitor that activates AMPK and SIRT1; improves cellular metabolic efficiency and may reduce insulin resistance

Protocols

• Weight Loss Protocol
• Metabolic Reset Protocol

Related Conditions

• Metabolic Syndrome
• Weight Management
• NAFLD
• Cardiac Health

Research Summary

Semaglutide's SUSTAIN 6 trial showed 26% MACE reduction in T2D patients (PMID-27633186). STEP 2 demonstrated weight loss efficacy in T2D + obesity (PMID-33667417). Retatrutide Phase 2 showed dose-dependent HbA1c reductions and up to 17% weight loss in T2D (PMID-37385280). NMN increased muscle insulin sensitivity in prediabetic women (Yoshino, Science; PMID-33888596). MOTS-C improves insulin sensitivity via AMPK activation (PMID-25738459).

Related

• Condition Index
• Protocol Index

#condition #metabolic-system